Fate Therapeutics マネジメント
マネジメント 基準チェック /34
Fate Therapeuticsの CEO はJ. Wolchkoで、 Dec2015年に任命され、 の在任期間は 8.92年です。 の年間総報酬は$ 3.52Mで、 18.3%給与と81.7%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.24%を直接所有しており、その価値は$ 608.19K 。経営陣と取締役会の平均在任期間はそれぞれ6.8年と13.8年です。
主要情報
J. Wolchko
最高経営責任者
US$3.5m
報酬総額
| CEO給与比率 | 18.3% |
| CEO在任期間 | 8.9yrs |
| CEOの所有権 | 0.2% |
| 経営陣の平均在職期間 | 6.8yrs |
| 取締役会の平均在任期間 | 13.8yrs |
経営陣の近況
Recent updates
Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options
Nov 20Industry Analysts Just Made An Incredible Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts
Aug 21
Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?
Aug 11Fate Therapeutics: Looking For A Potential Turnaround In 2024
Apr 29Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues
Apr 23Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%
Feb 16Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks
Jan 26Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry
Dec 19Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?
Sep 08Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price
Jun 07Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%
May 08Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?
Apr 17We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully
Jan 10Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation
Sep 22Fate Therapeutics: Yes For Speculators, No For Defensive Investors
Aug 30Needham initiates Fate coverage Therapeutics on potential of stem cell therapies
Jul 28Fate Therapeutics names Brian Powl as chief commercial officer
Jun 30Fate: Possible Speedy FDA Approval Process With RMAT Designation
Jun 03We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely
Jun 02Fate Therapeutics: Slowly Getting To An Attractive Position
Feb 21We're Not Very Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate
Feb 01CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$178m |
| Jun 30 2024 | n/a | n/a | -US$176m |
| Mar 31 2024 | n/a | n/a | -US$190m |
| Dec 31 2023 | US$4m | US$645k | -US$161m |
| Sep 30 2023 | n/a | n/a | -US$173m |
| Jun 30 2023 | n/a | n/a | -US$212m |
| Mar 31 2023 | n/a | n/a | -US$235m |
| Dec 31 2022 | US$8m | US$645k | -US$282m |
| Sep 30 2022 | n/a | n/a | -US$294m |
| Jun 30 2022 | n/a | n/a | -US$254m |
| Mar 31 2022 | n/a | n/a | -US$233m |
| Dec 31 2021 | US$12m | US$610k | -US$212m |
| Sep 30 2021 | n/a | n/a | -US$197m |
| Jun 30 2021 | n/a | n/a | -US$212m |
| Mar 31 2021 | n/a | n/a | -US$185m |
| Dec 31 2020 | US$6m | US$570k | -US$173m |
| Sep 30 2020 | n/a | n/a | -US$149m |
| Jun 30 2020 | n/a | n/a | -US$117m |
| Mar 31 2020 | n/a | n/a | -US$112m |
| Dec 31 2019 | US$11m | US$540k | -US$98m |
| Sep 30 2019 | n/a | n/a | -US$86m |
| Jun 30 2019 | n/a | n/a | -US$76m |
| Mar 31 2019 | n/a | n/a | -US$72m |
| Dec 31 2018 | US$4m | US$516k | -US$67m |
| Sep 30 2018 | n/a | n/a | -US$63m |
| Jun 30 2018 | n/a | n/a | -US$57m |
| Mar 31 2018 | n/a | n/a | -US$47m |
| Dec 31 2017 | US$1m | US$480k | -US$43m |
報酬と市場: J.の 総報酬 ($USD 3.52M ) は、 US市場 ($USD 1.47M ) の同規模の企業の平均を上回っています。
報酬と収益: J.の報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
J. Wolchko (54 yo)
8.9yrs
在職期間
US$3,522,750
報酬
Mr. J. Scott Wolchko is the Founder of Fate Therapeutics, Inc. and has been its Chief Executive Officer and President since December 1, 2015 & serves as It's CFO and CAO since June 3, 2024. Mr. Wolchko ser...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder | 8.9yrs | US$3.52m | 0.24% $ 608.2k | |
| Chief Legal & Compliance Officer and Corporate Secretary | 9.1yrs | US$2.82m | 0.053% $ 133.8k | |
| President of Research & Development | 6.8yrs | US$2.99m | 0.067% $ 168.6k | |
| Chief Regulatory & Quality Officer | 2.8yrs | データなし | 0.24% $ 613.1k | |
| Senior Vice President of Clinical Operations | less than a year | データなし | データなし |
6.8yrs
平均在職期間
52.5yo
平均年齢
経験豊富な経営陣: FATEの経営陣は経験豊富で経験豊富です（平均在職期間は6.8年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder | 9.1yrs | US$3.52m | 0.24% $ 608.2k | |
| Independent Chairman | 13yrs | US$253.25k | 0.54% $ 1.4m | |
| Independent Vice Chairman of the Board | 16.6yrs | US$218.33k | 0.27% $ 690.9k | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 10.7yrs | US$228.25k | 0.010% $ 25.2k | |
| Member of Scientific Advisory Board | 14.5yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 14.5yrs | データなし | データなし | |
| Independent Director | 11.3yrs | US$231.75k | 0.058% $ 147.2k | |
| Member of Scientific Advisory Board | 14.5yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 14.5yrs | データなし | データなし | |
| Independent Director | 5.7yrs | US$227.82k | 0.0086% $ 21.9k |
13.8yrs
平均在職期間
66.5yo
平均年齢
経験豊富なボード: FATEの 取締役会 は経験豊富で 経験豊富 です ( 13.8年の平均在任期間)。